Clinical trial
Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats
Name
sLAG-3 in brain ischemia
Description
This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:
* Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?
* Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?
Trial arms
Trial start
2023-04-01
Estimated PCD
2024-03-01
Trial end
2024-04-01
Status
Recruiting
Treatment
Serum Iron
Serum iron levels in study groups
Arms:
Control, Patients with acute Ischemic stroke
RBCs Alpha-synuclein
α-syn levels in RBCs
Arms:
Control, Patients with acute Ischemic stroke
Other names:
α-syn
Serum Soluble lymphocyte activation gene
sLAG-3 in the serum of study groups
Arms:
Control, Patients with acute Ischemic stroke
Other names:
sLAG-3
Brain computed tomography
Brain CT of patients after admission
Arms:
Control, Patients with acute Ischemic stroke
Other names:
CT
Brain Iron
Iron in brain homogenate of rats
Arms:
Control rats, Rats with ischemic stroke, Rats with ischemic stroke + deferoxamine
Brain Alpha-synuclein
α-syn expression in rat's brain
Arms:
Control rats, Rats with ischemic stroke, Rats with ischemic stroke + deferoxamine
Other names:
α-syn
Brain lymphocyte activation gene
LAG-3 expression in rat's brain
Arms:
Control rats, Rats with ischemic stroke, Rats with ischemic stroke + deferoxamine
Other names:
LAG-3
Deferoxamine
intramuscular deferoxamine (200 mg/kg) injection to rats
Arms:
Rats with ischemic stroke + deferoxamine
Size
48
Primary endpoint
Iron levels
6 months
Alpha-synuclein levels
6 months
Levels of Soluble lymphocyte activation gene-3
6 months
levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size
6 months
Iron levels in brain of rats
2 months
Levels of Alpha-synuclein expression in brain of rats
2 months
Levels of Lymphocyte activation gene-3 expression in brain of rats
2 months
Eligibility criteria
Inclusion Criteria:
1. Patients at the age between 50-70 years.
2. Patients having neurological symptoms of acute ischemic stroke.
Exclusion Criteria:
1. Patients with acute hemorrhagic stroke.
2. Patients with Parkinson's disease (PD).
3. Patients with dementia, and Alzheimer's disease.
4. Patients with any type of malignancy.
5. Patients with central nervous system infection.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 48, 'type': 'ESTIMATED'}}
Updated at
2023-04-25
1 organization
Organization
Aswan University Hospital